Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12928358 | 0.98 | HTR1A (0.69) | HTR1APOLBALDH1A1KDM4ETSHR | |
| SCHEMBL22350718 | 0.93 | HTR1A (0.69) | HTR1APOLBALDH1A1KDM4ETSHR | |
| SCHEMBL5495402 | 0.90 | HTR1A (0.55) | HTR1APOLBALDH1A1KDM4ETSHR | |
| Alanine SCHEMBL28004622 | 0.87 | HTR1A (0.53) | HTR1APOLBALDH1A1KDM4ETSHR | |
| Alanine SCHEMBL27702084 | 0.85 | HTR1A (0.55) | HTR1APOLBALDH1A1KDM4ETSHR | |
| SCHEMBL18918295 | 0.83 | HTR1A (0.49) | HTR1APOLBALDH1A1KDM4ETSHR | |
| SCHEMBL27819740 | 0.83 | HTR1A (0.53) | HTR1APOLBALDH1A1KDM4ETSHR | |
| Diethylcarbamazine SCHEMBL1819685 | 0.80 | HTR1A (1.00) | HTR1APOLBALDH1A1KDM4ETSHR | |
| Diethylcarbamazine SCHEMBL67289 | 0.80 | HTR1A (1.00) | HTR1APOLBALDH1A1KDM4ETSHR | |
| SCHEMBL29626142 | 0.80 | HTR1A (0.44) | HTR1APOLBALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-2203437-A1 | CHIRAL CIS-IMIDAZOLINES | F. Hoffmann-Roche AG (CH) | 2010-07-07 | — | — | EP | claimed |
| WO-2009047161-A1 | CHIRAL CIS-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| EP-1960368-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007063013-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| EP-0832061-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6054457-A | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-25 | — | — | US | disclosed |
| EP-0832061-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996041795-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | HTR1A 69/4885POLB 3645/4885ALDH1A1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.